Icatibant acetate: Treatment of hereditary angioedema agent for liver cirrhosis antiasthmatic drug treatment of osteoarthritis pain bradykinin B 2 antagonist

Drugs of the Future

Volumn 31, Issue 2, 2006, Pages 101-106

  Sorbera, L A ^a   Fernandez Forner D ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR ANTAGONIST; HISTAMINE; ICATIBANT; PLACEBO; SEROTONIN;

ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; DRUG ACTIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HYPERSALIVATION; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; LIVER CIRRHOSIS; OSTEOARTHRITIS; RESTLESSNESS; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33646228840     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.02.970170     Document Type: Review

References (43)

1. Henke, S., Anagnostopulos, H., Breipohl, G., Knolle, J., Stechel, J., Schölkens, B., Fehlhaber, H.-W. (Sanofi-Aventis). Peptides having a bradykinin-inhibiting activity. AU 8939431, EP 0370453, JP 1990184697.
2. Henke, S., Anagnostopulos, H., Breipohl, G., Knolle, J., Steehl, J., Schölkens, B., Fehlhaber, H.-W., Gerhards, H., Hock, F. (Sanofi-Aventis Deutschland GmbH). Peptides having bradykinin antagonist action. DE 3938751, US 5648333.
3. 2 receptor antagonist peptide Hoe 140. J Pept Res 2002, 59: 139-48.
4. 2 receptor as a potential therapeutic target. Drug News Perspect 2000, 13: 213-25.
5. Bhoola, K.D., Figueroa, C.D., Worthy, K. Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 1992,44: 1-80.
6. Regoli, D., Babare, J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980, 32: 1-46.
7. Regoli, D., Rhaleb, N.E., Drapeau, G., Dion, S. Kinin receptor subtypes. J Cardiovasc Pharmacol 1990, 15(Suppl. 6): S30-8.
8. Röscher, A.A., Klier, C., Dengler, D., Faussner, A., Muller-Esterl, W. Regulation of bradykinin action at the receptor level. J Cardiovasc Pharmacol 1990, 15(Suppl. 6): S39-43.
9. Hess, J.F., Borkowski, J.A., Young, G.S., Strader, D., Ransom, R.W. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun 1992, 184: 260-8.
10. 1 receptor. J Biol Chem 1994, 269: 21583-6.
11. Hall, JM Bradykinin receptors. Gen Pharmacol 1997, 28: 1-6.
12. Davis, A.E. III. The pathophysiology of hereditary angioedema. Clin Immunol 2005, 114: 3-9.
13. Zuraw, B.L. Current and future therapy for hereditary angioedema. Clin Immunol 2005, 114: 10-6.
14. Wirth, K.J., Heitsch, H., Scholkens, B. Kinin receptor antagonists. Unique probes in basic and clinical research. Can J Physiol Pharmacol 1995, 73: 797-804.
15. Proud, D., Kaplan, A.P. Kinin formation: Mechanism and role in inflammatory disorders. Annu Rev Immunol 1988, 6: 49-83.
16. Manning, D.C., Raja, S.N., Meyer, R.A., Campbell, J.N. Pain and hyperalgesia after intradermal injection of bradykinin in humans. Clin Pharmacol Ther 1991, 50: 721-9.
17. Gepetti, P. Sensory neuropeptide release by bradykinin: Mechanisms and pathophysiological implications. Regul Pept 1993,47: 1-23.
18. Griesbacher, T., Lembeck, F. Effect of the bradykinin antagonist HOE 140 in experimental acute pancreatitis. Br J Pharmacol 1992, 107: 356-60.
19. Otterbein, L., Lowe, V.C., Kyle, D.J., Noronha-Blob, L. Additive effects of the bradykinin antagonist, NPC 17761, and a leumedin, APC 15669, on survival in animal models of sepsis. Agents Actions 1993, 39: C125-7.
20. Narotam, P.K., Rodell, T., Nadvi, S.S., Bhoola, K.D., Troha, J.M., Parbhoosingh, R., van Dellen, J.R. Traumatic brain contusions. A clinical role for the kinin antagonist CP-0127. Acta Neurochir 1998, 140: 793-802.
21. 4-induced liver cirrhosis: Possible role of enhanced microvascular leakage. Eur J Pharmacol 1997, 337: 45-53.
22. Stewart, J.M., Gera, L., Chan, D.C. Dimers of bradykinin and substance P antagonists as potential anti-cancer drugs. Pept Sci 1999, 1: 731-2.
23. Lembeck, F., Wirth, K., Winkler, I., Breipohl, G., Henkse, S., Knolle, J. (Sanofi-Aventis). Use of bradykinin antagonists for the treatment of viral diseases. CA 2138933, EP 661058, JP 1995206703, US 5789383.
24. Björck, L., Sjöbring, U., Ben Nasr, A., Olsen, A., Herwald, H., Muller-Esterl, W. (Active Biotech AB.) Use of kinin antagonists for preparing a pharmaceutical composition for treating bacterial infections. US 6221845, WO 1997044353.
25. Hock, F.J., Wirth, K., Albus, U. et al. Hoe 140, a new potent and long acting bradykinin-antagonist: In vitro studies. Br J Pharmacol 1991, 102: 769-73.
26. 2 receptor antagonist, Hoe 140, in isolated blood vessels from different species. Br J Pharmacol 1994, 112: 683-9.
27. Félétou, M., Martin, C.A.E., Molimard, M., Naline, E. Germain, M., Thurieau, C., Fauchère J.-L. Canet, E., Advenier, C. In vitro effects of HOE 140 in human bronchial, and vascular tissue. Eur J Pharmacol 1995, 274: 57-64
28. 2 selective receptor antagonists. Eur J Pharmacol 2003, 460: 75-83.
29. Eric, J., Gabra, B.H., Sirois, P. Implication of the bradykinin receptors in antigen-induced pulmonary inflammation in mice. Br J Pharmacol 2003, 138: 1589-97.
30. Sakamoto, T., Elwood, W., Barnes, P.J., Chung, K.F. Effects of Hoe 140, a new bradykinin receptor antagonist on bradykinin- and platelet-activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig. Eur J Pharmacol 1992, 213: 367-73.
31. 2 antagonist HOE 140 inhibits late allergic microvascular leakage in guinea pig airways. Immunopharmacology 1999, 43: 249-53.
32. Wirth, K., Hock, F.J., Albus, U. et al. Hoe 740, a new potent and long-acting bradykinin-antagonist: In vivo studies. Br J Pharmacol 1991, 102: 774-7.
33. Sharma, J.N., Wirth, K.J. Inhibition of rats adjuvant arthritis by a bradykinin antagonist Hoe 140 and its influence on kallikreins. Gen Pharmacol 1996, 27: 133-6.
34. Santiago, J.A., Osei, S.Y., Kadowitz, P.J. Inhibitory effects of Hoe 140 on vasodilator responses to bradykinin in the mesenteric vascular bed of the cat. Eur J Pharmacol 1993, 236: 315-8.
35. Subcutaneous icatibant produces positive results in bioavailability study. DailyDrugNews.com (Daily Essentials) April 16, 2004.
36. Rousso, P., Nguyen, M., Perrin, Y. et al. Icatibant has no impact on renal function in healthy subjects. Clin Pharmacol Ther 2004, 75(2): Abst P11-19.
37. Perrin, Y., Nguyen, M. T., Rousso, P. et al. Pharmacokinetic and pharmacodynamic profile of icatibant. Clin Pharmacol Ther 2004, 75(2): Abst P11-16.
38. 2 receptor antagonist, improves natriuresis and diuresis after sodium challenge in patients with liver cirrhosis. Hepatology 2004, 40(4. Suppl. 1): Abst 1092.
39. Flechtenmacher, J., Talke, M., Veith, D., Heil, K., Gebauer, A., Schoenharting, M. Bradykinin-receptor-inhibition - A therapeutic option in osteoarthritis? Osteoarthritis Cartilage 2004, 12(Suppl. B): Abst P332.
40. Akbary, A.M., Wirth, K.J., Schölkens, B.A. Efficacy and tolerability of icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology 1996, 238: 238-42.
41. 2 receptor antagonist in treatment of hereditary angioedema. Clin Pharmacol Ther 2005, 77(2): Abst P1-23.
42. Subcutaneous treatment with icatibant for acute attacks of hereditary angioedema (NCT00097695). ClinicalTrials.gov Web Site 2005. December 8.
43. Kos and Jerini sign agreement for icatibant in U.S. and Canada. DailyDrugNews.com (Daily Essentials) November 9. 2005.